2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Nonalcoholic fatty liver disease (NAFLD) is a common condition in patients with obesity. Bariatric surgery has often been proposed as a viable treatment option, but the ideal surgical procedure remains unclear. Inconsistently, reports on postoperative deterioration of liver function put further doubt on which technique to apply. Aim of this study was to assess the impact of Roux-en-Y-gastric bypass (RYGB) and sleeve gastrectomy (SG) on the postoperative recovery of liver function.

          Methods

          A total of 175 patients with obesity that underwent bariatric surgery in our institution were included in this prospective cohort study. BMI, laboratory values, and liver function capacity (using LiMAx) were assessed preoperatively and at 6 and 12 months postoperatively. Generalized linear model (GLM) was performed to determine variables influencing liver function capacity after the operation.

          Results

          Prior to operations, 64% of patients presented with a diminished liver function capacity, as measured by LiMAx test. Liver function capacity significantly recovered after 12 months in the SG group (300 μg/kg/h preop vs. 367 μg/kg/h postop) but not in the RYGB group (306 μg/kg/h preop vs. 349 μg/kg/h). Preoperative factors impeding liver function recovery included type 2 diabetes mellitus (T2DM), weight, male sex, AST/thrombocyte ratio (APRI), and gamma-glutamyltransferase (GGT).

          Conclusion

          Bariatric surgery, especially sleeve gastrectomy, leads to an improvement of liver function. However, in some patients with T2DM, higher preoperative weight and male sex postoperative deterioration of liver function capacity may occur.

          Graphical abstract

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

          NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Non-alcoholic fatty liver disease – A global public health perspective

            As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

                Bookmark

                Author and article information

                Contributors
                sopschmitz@ukaachen.de
                akroh@ukaachen.de
                akoch@ukaachen.de
                jbrozat@ukaachen.de
                Christine.Stier@Sana.de
                uneumann@ukaachen.de
                fulmer@ukaachen.de
                palizai@ukaachen.de
                Journal
                Obes Surg
                Obes Surg
                Obesity Surgery
                Springer US (New York )
                0960-8923
                1708-0428
                4 April 2021
                4 April 2021
                2021
                : 31
                : 7
                : 3218-3226
                Affiliations
                [1 ]GRID grid.412301.5, ISNI 0000 0000 8653 1507, Department of General-, Visceral- and Transplantation Surgery, , RWTH Aachen University Hospital, ; Pauwelsstr. 30, 52074 Aachen, Germany
                [2 ]GRID grid.412301.5, ISNI 0000 0000 8653 1507, Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, , RWTH Aachen University Hospital, ; Pauwelsstr. 30, 52074 Aachen, Germany
                [3 ]Obesity Center NRW, Sana Kliniken, Hürth, Germany
                [4 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Surgery, , Maastricht University Medical Center, ; P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
                Author information
                http://orcid.org/0000-0001-6732-1595
                Article
                5390
                10.1007/s11695-021-05390-1
                8175244
                33813683
                9fbbe9d6-034c-4ce7-981d-68e001afdf40
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 10 November 2020
                : 21 March 2021
                : 25 March 2021
                Funding
                Funded by: Universitätsklinikum RWTH Aachen (8915)
                Categories
                Original Contributions
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2021

                Surgery
                nafld,liver function,limax,sleeve gastrectomy,roux-en-y-gastric bypass,bariatric surgery
                Surgery
                nafld, liver function, limax, sleeve gastrectomy, roux-en-y-gastric bypass, bariatric surgery

                Comments

                Comment on this article